Research Article
The Prognostic Values of Leukocyte Rho Kinase Activity in Acute Ischemic Stroke
Table 2
Demographics of entire cohort in ischemic stroke group.
| | | Ischemic stroke patients
() |
| | Age (years) | 64.9 ± 12.1 | | Male (%) | 77 (70.0%) | | Risk factors | | | Hypertension (%) | 78 (70.9%) | | Dyslipidemia* (%) | 44 (40.0%) | | Diabetes mellitus (%) | 36 (32.7%) | | Current smoker (%) | 34 (30.9%) | | History of atrial fibrillation | 8 (7.3%) | | TOAST etiology | | | Macroangiopathy | 40 (36.4%) | | Microangiopathy | 49 (44.5%) | | Embolic | 8 (7.3%) | | Cryptogenic | 13 (11.8%) | | Hemorrhagic transformation | 12 (10.9%) | | Territory | | | ACA | 5 (4.5%) | | MCA | 65 (59.1%) | | PCA and VB | 28 (25.5%) | | Undetermined | 12 (10.9%) | | NIHSS score at admission | 6.4 ± 6.8 | | Medication at discharge | | | Aspirin | 80 (72.7%) | | Clopidogrel | 18 (16.4%) | | Warfarin | 2 (1.8%) | | Beta blocker | 17 (15.5%) | | CCB | 33 (30.0%) | | ACEI/ARB | 41 (37.2%) | | Diuretics | 2 (1.8%) | | Statin | 42 (38.2%) |
|
|
*Dyslipidemia: LDL > 160 mg/dL, triglyceride > 150 mg/dL, HDL < 40 mg/dL in male, or HDL < 50 mg/dL in female.
ACA: anterior cerebral artery; ACEI: angiotensin converting enzyme inhibitor; ARB: angiotensin receptor blocker; CCB: calcium channel blocker; MCA: middle cerebral artery; NIHSS: National Institute of Health Stroke Scale; PCA: posterior cerebral artery; TOAST: acute stroke treatment; VBA: vertebrobasilar artery.
|
